Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1401 vaccine combination in advanced solid tumors
NCT02661100Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2017
- Primary completion
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
01
Overview
Phase 2, open-label trial of CDX-1401 in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC) and 3 more, sponsored by Case Comprehensive Cancer Center. Planned start Jan 2017; status: withdrawn.
02
Drugs
CDX-1401
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)small cell lung cancer (SCLC)urothelial carcinoma (UC)mesothelioma
Beyond the preview
Go deeper on NCT02661100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661100.